Relevant bibliographies by topics / Antimalarials

Academic literature on the topic 'Antimalarials'

Author: Grafiati
Published: 4 June 2021
Last updated: 30 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antimalarials.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antimalarials"

1

Kwofie, Samuel K., Emmanuel Broni, Bismark Dankwa, Kweku S. Enninful, Joshua Teye, Cedar R. Davidson, Josephine B. Nimely, et al. "Review of Atypical Organometallic Compounds as Antimalarial Drugs." Journal of Chemistry 2020 (May 20, 2020): 1–9. http://dx.doi.org/10.1155/2020/9414093.

Full text
Abstract:
Organometallic compounds are molecules that contain at least one metal-carbon bond. Due to resistance of the Plasmodium parasite to traditional organic antimalarials, the use of organometallic compounds has become widely adopted in antimalarial drug discovery. Ferroquine, which was developed due to the emergence of chloroquine resistance, is currently the most advanced organometallic antimalarial drug and has paved the way for the development of new organometallic antimalarials. In this review, a general overview of organometallic antimalarial compounds and their antimalarial activity in comparison to purely organic antimalarials are presented. Furthermore, recent developments in the field are discussed, and future applications of this emerging class of therapeutics in antimalarial drug discovery are suggested.
APA, Harvard, Vancouver, ISO, and other styles
2

Esdaile, John M. "The Efficacy of Antimalarials in Systemic Lupus Erythematosus." Lupus 2, no. 1_suppl (February 1993): 3–8. http://dx.doi.org/10.1177/0961203393002001021.

Full text
Abstract:
The use of antimalarial drugs to treat systemic lupus erythematosus (SLE) is reviewed regarding their value in SLE of mild-to-moderate disease activity, as corticosteroid-sparing agents, and as an adjunctive therapy in severe SLE. A retrospective controlled study of a variety of antimalarials and a randomized discontinuation trial of hydroxychloroquine support the considerable clinical belief that antimalarials are of benefit in mild-to-moderate SLE. Anecdotal reports and the opinion of experienced clinicians suggest that antimalarials permit the use of lower doses of corticosteroids. No controlled study has confirmed a corticosteroid-sparing role for antimalarials, although no controlled study has been conducted specifically to address this hypothesis. The data on antimalarials in severe SLE are scant. Antimalarials are likely effective in at least a subgroup of SLE patients with mild-to-moderate disease activity. Whether these agents are corticosteroid sparing and prevent severe disease exacerbations is unproven. Given the low toxicity of antimalarials, further studies are clearly warranted.
APA, Harvard, Vancouver, ISO, and other styles
3

Opsenica, Igor, Dejan Opsenica, Milka Jadranin, Kirsten Smith, Wilbur Milhous, Manolis Stratakis, and Bogdan Solaja. "On peroxide antimalarials." Journal of the Serbian Chemical Society 72, no. 12 (2007): 1181–90. http://dx.doi.org/10.2298/jsc0712181o.

Full text
Abstract:
Several dicyclohexylidene tetraoxanes were prepared in order to gain a further insight into structure-activity relationship of this kind of antimalarials. The tetraoxanes 2-5, obtained as a cis/trans mixture, showed pronounced antimalarial activity against Plasmodium falciparum chloroquine susceptible D6, chloroquine resistant W2 and multidrug-resistant TM91C235 (Thailand) strains. They have better than or similar activity to the corresponding desmethyl dicyclohexylidene derivatives. Two chimeric endoperoxides with superior antimalarial activity to the natural product ascaridole were also synthesized.
APA, Harvard, Vancouver, ISO, and other styles
4

Evans, Daniel R., Colleen R. Higgins, Sarah K. Laing, Phyllis Awor, and Sachiko Ozawa. "Poor-quality antimalarials further health inequities in Uganda." Health Policy and Planning 34, Supplement_3 (December 1, 2019): iii36—iii47. http://dx.doi.org/10.1093/heapol/czz012.

Full text
Abstract:
Abstract Substandard and falsified medications are a major threat to public health, directly increasing the risk of treatment failure, antimicrobial resistance, morbidity, mortality and health expenditures. While antimalarial medicines are one of the most common to be of poor quality in low- and middle-income countries, their distributional impact has not been examined. This study assessed the health equity impact of substandard and falsified antimalarials among children under five in Uganda. Using a probabilistic agent-based model of paediatric malaria infection (Substandard and Falsified Antimalarial Research Impact, SAFARI model), we examine the present day distribution of the burden of poor-quality antimalarials by socio-economic status and urban/rural settings, and simulate supply chain, policy and patient education interventions. Patients incur US$26.1 million (7.8%) of the estimated total annual economic burden of substandard and falsified antimalarials, including $2.3 million (9.1%) in direct costs and $23.8 million (7.7%) in productivity losses due to early death. Poor-quality antimalarials annually cost $2.9 million to the government. The burden of the health and economic impact of malaria and poor-quality antimalarials predominantly rests on the poor (concentration index −0.28) and rural populations (98%). The number of deaths among the poorest wealth quintile due to substandard and falsified antimalarials was 12.7 times that of the wealthiest quintile, and the poor paid 12.1 times as much per person in out-of-pocket payments. Rural populations experienced 97.9% of the deaths due to poor-quality antimalarials, and paid 10.7 times as much annually in out-of-pocket expenses compared with urban populations. Our simulations demonstrated that interventions to improve medicine quality could have the greatest impact at reducing inequities, and improving adherence to antimalarials could have the largest economic impact. Substandard and falsified antimalarials have a significant health and economic impact, with greater burden of deaths, disability and costs on poor and rural populations, contributing to health inequities in Uganda.
APA, Harvard, Vancouver, ISO, and other styles
5

Agbo, Chinonyelum Emmanuel, Uzochukwu Emmanuel Chima, Sunday Chibueze Ogbobe, Faith Olanrewaju Omotayo, and Success Chekwubechukwu David. "Transdermal antimalarial drug delivery to improve poor adherence to antimalarials: A new light at the end of the tunnel." American Journal of Biopharmacy and Pharmaceutical Sciences 3 (December 2, 2023): 4. http://dx.doi.org/10.25259/ajbps_14_2023.

Full text
Abstract:
Malaria, a perilous disease caused by Plasmodium parasites and characterized by a substantial mortality rate, has persistently posed as a global health challenge. Conventional antimalarial formulations, although effective, grapple with issues surrounding their bioavailability and palatability, and potentially hampering patient adherence and inadvertently fueling drug resistance and poor treatment outcomes. This paper meticulously delves into the predicaments associated with prevailing antimalarial delivery methods – oral, intravenous, and intramuscular. The paper navigates through the compelling merits of the transdermal pathway, drawing inspiration from its triumphant deployment in other medical realms. The investigation extends to encompass preclinical inquiries dedicated to exploring the transdermal administration of antimalarials. Transdermal antimalarials have shown complete suppression and elimination of Plasmodium parasites, as suggested by the preclinical studies. These preclinical studies emerge as a beacon of hope, exhibiting heightened bioavailability, enhanced safety margins, and notable cost-effectiveness when compared with oral antimalarials. Moreover, this innovative avenue for drug delivery not only offers convenience but also holds the potential to be a transformative solution to the adherence problems of traditional antimalarials, which currently afflicts standard therapeutic options.
APA, Harvard, Vancouver, ISO, and other styles
6

Zieliński, Ewa, Marek Kowalczyk, Karolina Osowiecka, Łukasz Klepacki, Łukasz Dyśko, and Katarzyna Wojtysiak. "The Problem of Antimalarial-Drug Abuse by the Inhabitants of Ghana." Medicina 59, no. 2 (January 29, 2023): 257. http://dx.doi.org/10.3390/medicina59020257.

Full text
Abstract:
Introduction: Malaria is still a huge social and economic health problem in the world. It especially affects the developing countries of Africa. A particular problem is the misuse and abuse of over-the-counter antimalarials. This problem could lead to the emergence of drug-resistant strains and the subsequent elimination of more antimalarials from the list of effective antimalarials in Ghana. Methods: During the implementation of the study, an original questionnaire was used to collect data among Ghanaians on their knowledge of malaria, attitude towards antimalarials and their use of antimalarials. Results: The proportion in the analyzed subgroups was compared using the chi-square test. The analysis was conducted using TIBCO Software Inc., Krakow, Poland (2017) and Statistica (data analysis software system), version 13. In total, 86.29% of respondents knew the symptoms of malaria (p = 0.02) and 57.2% knew the cause of malaria (p < 0.001). Respondents with higher education were significantly more likely to know the symptoms of malaria (96%) p < 0.001. In the study group, only 74.59% of the respondents consulted medical personnel before taking the antimalarial drug (p = 0.51) and only 14.2% of the remaining respondents performed a rapid diagnostic test for malaria. Conclusions: The awareness of Accra and Yendi native inhabitants about the causes and symptoms of malaria and alternative ways of prevention is quite high. People’s education very significantly influences the way Accra residents deal with suspected malaria. Widespread public education and awareness and accessibility to places where antimalarial drugs are sold play a very important role in the proper use of antimalarial drugs.
APA, Harvard, Vancouver, ISO, and other styles
7

Yousif, M. A., and A. A. Adeel. "Antimalarials prescribing patterns in Gezira state: precepts and practices." Eastern Mediterranean Health Journal 6, no. 5-6 (December 15, 2000): 939–47. http://dx.doi.org/10.26719/2000.6.5-6.939.

Full text
Abstract:
A longitudinal pharmacoepidemiological study on prescribing patterns of antimalarials was conducted in Gezira State, Sudan. Different core drug prescribing indicators were identified, measured and correlated. Chloroquine and quinine were the most frequently prescribed antimalaria drugs but in 44.7% of cases, the dosage was inappropriate and did not conform to standard regimens. Due to variable and unmonitored patterns of drug resistance, most medical practitioners in Sudan tend to follow their own protocols to treat severe cases of malaria rather than conforming to standard regimens. We attribute the emergence of a high rate of resistance to malaria chemotherapy to such practices. We recommend interventions to ensure rational prescribing, and call for the formulation of a national antimalarial drugs policy.
APA, Harvard, Vancouver, ISO, and other styles
8

Heppner, DG, PE Hallaway, GJ Kontoghiorghes, and JW Eaton. "Antimalarial properties of orally active iron chelators." Blood 72, no. 1 (July 1, 1988): 358–61. http://dx.doi.org/10.1182/blood.v72.1.358.358.

Full text
Abstract:
Abstract The appearance of widespread multiple drug resistance in human malaria has intensified the search for new antimalarial compounds. Metal chelators, especially those with high affinity for iron, represent one presently unexploited class of antimalarials. Unfortunately the use of previously identified chelators as antimalarials has been precluded by their toxicity and, in the case of desferrioxamine, the necessity for parenteral administration. The investigators now report that a new class of orally active iron chelators, namely the derivatives of alpha- ketohydroxypyridines (KHPs), are potent antimalarials against cultured Plasmodium falciparum. The KHPs evidently exert this effect by sequestering iron because a preformed chelator:iron complex has no antimalarial action. The pool(s) of iron being sequestered by the chelators have not been identified but may not include serum transferrin. Preincubation of human serum with KHPs followed by removal of the drug results in the removal of greater than 97% of total serum iron. Nonetheless, this serum effectively supports the growth of P falciparum cultures. Therefore the KHPs may exert antimalarial effect through chelation of erythrocytic rather than serum iron pool(s). The investigators conclude that these powerful, orally active iron chelators may form the basis of a new class of antimalarial drugs.
APA, Harvard, Vancouver, ISO, and other styles
9

Heppner, DG, PE Hallaway, GJ Kontoghiorghes, and JW Eaton. "Antimalarial properties of orally active iron chelators." Blood 72, no. 1 (July 1, 1988): 358–61. http://dx.doi.org/10.1182/blood.v72.1.358.bloodjournal721358.

Full text
Abstract:
The appearance of widespread multiple drug resistance in human malaria has intensified the search for new antimalarial compounds. Metal chelators, especially those with high affinity for iron, represent one presently unexploited class of antimalarials. Unfortunately the use of previously identified chelators as antimalarials has been precluded by their toxicity and, in the case of desferrioxamine, the necessity for parenteral administration. The investigators now report that a new class of orally active iron chelators, namely the derivatives of alpha- ketohydroxypyridines (KHPs), are potent antimalarials against cultured Plasmodium falciparum. The KHPs evidently exert this effect by sequestering iron because a preformed chelator:iron complex has no antimalarial action. The pool(s) of iron being sequestered by the chelators have not been identified but may not include serum transferrin. Preincubation of human serum with KHPs followed by removal of the drug results in the removal of greater than 97% of total serum iron. Nonetheless, this serum effectively supports the growth of P falciparum cultures. Therefore the KHPs may exert antimalarial effect through chelation of erythrocytic rather than serum iron pool(s). The investigators conclude that these powerful, orally active iron chelators may form the basis of a new class of antimalarial drugs.
APA, Harvard, Vancouver, ISO, and other styles
10

Tang, Yu-Qing, Qian Ye, He Huang, and Wei-Yi Zheng. "An Overview of Available Antimalarials: Discovery, Mode of Action and Drug Resistance." Current Molecular Medicine 20, no. 8 (December 29, 2020): 583–92. http://dx.doi.org/10.2174/1566524020666200207123253.

Full text
Abstract:
: Malaria is one of the three most deadly infectious diseases in the world and seriously endangers human health and life. To reduce the public health burden of this disease, scientists have focused on the discovery and development of effective antimalarial drugs, from quinine and chloroquine to antifolates and artemisinin and its derivatives, which all play a profound role in the treatment of malaria. However, drugresistant strains of Plasmodium falciparum have emerged due to frequent use of antimalarials and have become increasingly resistant to existing antimalarial drugs, causing disastrous consequences in the world. In particular, artemisinin resistance is of greatest concern which was reported in 2008. Resistance to artenisinins has been a major obstacle for malaria control, and current efforts to curb artemisinin resistance have not been successful. Based on the current situation, it is urgent to develop more effective new antimalarials with distinct targets from conventional antimalarials in the world, which could facilitate to minimize the phenomenon of drug resistance. This review aims to summarize different kinds of antimalarial therapeutic efficacy, mechanisms of action and resistance, and proposes new solutions aiming towards further improvement of malaria elimination.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Antimalarials"

1

Meurer, Michael. "Childhood Discoid Lupus erythematosus and Antimalarials." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-135574.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Al-Tayib, Yousuf A. "Oxidative hepatic metabolism of cinchona antimalarials." Thesis, University of Bradford, 1990. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.304177.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Rajab, M. "Investigating calcium channel blockers as antimalarials." Thesis, University of Salford, 2018. http://usir.salford.ac.uk/47791/.

Full text
Abstract:
The rise in resistance to current antimalarial drugs has led researchers to consider drug repositioning as a quicker alternative for drug development and discovery. Preliminary drug repositioning screens carried out at the University of Salford identified calcium channel blockers (CCBs) as potential antimalarial agents. A growing body of evidence has demonstrated the importance of calcium within the Plasmodium life cycle. Studies have shown CCBs and calmodulin inhibitors to exhibit antimalarial activity. The research carried out in this project aims to evaluate the antimalarial efficacy, safety profile, mode of action and drug interactivity of the commercially available CCB and calmodulin inhibitor fendiline, and a range of its synthetic analogues. Initial screening of fendiline alone and in combination with commercially available drugs was carried out using a SYBR Green (SG) plate reader assay. Both CalcuSyn-based combination studies and a chloroquine potentiation assay were carried out. This was succeeded by the synthesis of fendiline analogues, which were carried out via a two-step synthetic route starting with a palladium catalysed coupling reaction followed by a reductive amination. Both the antimalarial activity and the cytotoxicity of the synthesised compounds were evaluated which led to a lead candidate to be selected (the hydroxy fendiline analogue, 4c). Further investigations into the activity, stage specificity and the effect compound 4c has on the hERG channel was carried out to develop a preliminary understanding of the mode of action of the compound. Finally, optimisation experiments to develop a flow cytometry-based assay that would detect fluctuations in calcium levels within infected red blood cells (RBCs) were performed. The conducted research showed the commercially available fendiline to have activity towards the multi-drug resistant Plasmodium falciparum K1 strain within the micromolar range (IC50 = 3.74 ± 0.64 μM). CalcuSyn-based combinations studies showed fendiline to have either an antagonistic or additive effect with currently available drugs. Interestingly, fendiline was found to reverse chloroquine resistance, similar to verapamil, however at half the concentration required for verapamil. Furthermore, the range of synthesised fendiline analogues identified several compounds that exhibited more activity towards the P. falciparum infected RBCs. The 2’ hydroxyl fendiline analogue (4c) was 5.6-fold more potent than fendiline itself (IC50 = 0.67 ± 0.21 μM) on the P. falciparum K1 strain, with an almost one-hundred-fold difference between antimalarial activity and cytotoxicity. The compound was found to be slow acting that targets the schizont stages of the parasite blood stages. The hERG channel inhibition assay gave an IC50 of 4.03 ± 0.52 μM, which is within the range that most small compounds fall within (1-10 μM). Finally, the optimisation experiments showed the developed method was only sensitive to dramatic calcium changes within RBCs and not within the parasites themselves. Further work is required to improve the sensitivity of the assay. In conclusion, the hydroxy fendiline compound provides an interesting candidate to investigate further as a combinatory partner with other antimalarials, and as a scaffold to synthesise other potentially more potent fendiline analogues.
APA, Harvard, Vancouver, ISO, and other styles
4

Meurer, Michael. "Childhood Discoid Lupus erythematosus and Antimalarials." Karger, 2003. https://tud.qucosa.de/id/qucosa%3A27661.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Nicoleti, Nélio Henrique [UNESP]. "Estrutura eletrônica de materiais orgânicos: moléculas antimalariais de sulfonamidas e anilinoquinolinas." Universidade Estadual Paulista (UNESP), 2007. http://hdl.handle.net/11449/88499.

Full text
Abstract:
Made available in DSpace on 2014-06-11T19:23:30Z (GMT). No. of bitstreams: 0 Previous issue date: 2007-05-11Bitstream added on 2014-06-13T20:10:54Z : No. of bitstreams: 1 nicoleti_nh_me_bauru.pdf: 1244120 bytes, checksum: 82b0fc15919f6c3214248fe48efec3e6 (MD5)
Neste trabalho estudamos dois grupos de moléculas: as anilinoquinolinas e as sulfonamidas, inibidores do Plasmodium causador da malária, com o objetivo de correlacionar a estrutura eletrônica com a atividade antimalarial. Em nossas buscas utilizamos métodos empíricos e semi-empíricos para o estudo conformacional e obtenção dos descritores eletrônicos. Também aplicamos vários métodos estatísticos como: Regressão Linear Simples e Múltipla, Análise de Componentes Principais (PCA) e Análise Discriminante Linear (LDA), para verificar uma possível correlação estrutura-atividade dessas moléculas. Os resultados apontaram os descritores eletrônicos mais relevantes na classificação das moléculas antimalariais.
In this work we study two groups of antimalarial compounds: the anilinoquinolines and sulfonamides, aiming the correlation of the electronic structure with the antimalarial activity. In our studies we employ empirical and semi empirical quantum chemistry methods for the geometry optimization and calculation of the electronic descriptors. Also we employed the statistical methods Simple and Multiple Linear Regression, Principal Component Analysis (PCA) and Linear Discriminating Analysis (LDA), to verify the existence of a possible structure-activity correlation for these compounds. The results of this work have pointed out the best electronic descriptors in the classification of the active compounds.
APA, Harvard, Vancouver, ISO, and other styles
6

Zindrou, Sherwan. "Molecular diagnosis of drug resistance in Plasmodium falciparum and virulence factors in Entamoeba histolytica /." Stockholm, 2000. http://diss.kib.ki.se/2000/91-628-4304-4/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hayes, Daniel Joseph. "Developing age-based dosing regimens for antimalarials." Thesis, University of Liverpool, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.570625.

Full text
Abstract:
Introduction. Age-based dosing of antimalarials is a widely used alternative to weight-based dosing practices. However, it is rarely taken into account in the drug development phase and standardized methods to devise age-based proxies that optimize the effectiveness and safety of antimalarial drugs do not exist. This has contributed to the variation in existing age-based regimens for antimalarials, at times resulting in poor, but widely-used regimens. Inaccurate dosing poses a threat to the individual (treatment failure, adverse effects) and the population (emergence and spread of resistance). Objectives. To address the lack of standardization and optimization in the development of age- based dosing regimens for antimalarials through the creation of regional weight-for-age growth ,,;,. .... references and the development and testing of a tool that uses these r~rer;JCes to calculate optimized age-based dosing regimens to inform drug developers and policy makers. Methods. To meet the objectives the following three steps were taken. First, a population representative reference data set was compiled. Secondly this data set was used to model regionally representative growth references. Finally these references were applied in a modelling tool to optimise age-based dosing regimens. Together with a team of expert statisticians, I developed a method to model multi-source anthropometric data to generate regional weight-for-age reference curves. I compiled a weight-for-age reference database from malaria-endemic countries using population representative data from health surveys and individual studies. An extension of the new generalized additive model for location, scale and shape (GAMLSS) was developed to generate smoothed country level curves, interpolating missing data from adjacent age categories and neighbouring countries with similar weigh-for- age distributions. These were combined in a finite mixture model weighted by population size or by population at risk of malaria to obtain regional weight-for-age growth references. In combination with drug specific parameters such as the therapeutic dose range and tablet strength, and regimen specific criteria such as the number of age categories and the use of tablet fractions, I determined age cut-offs that would result in regimens with the lowest number of patients receiving drugs outside the therapeutic range. The tool was initially used to support the development of age-based dosing regimens for the new fixed-dose combination of artesunate+mefloquine for Africa, Latin America and the Asia-Pacific regions and for specific countries (i.e. Cambodia and Brazil). I then evaluated the predicted dosing accuracy of all age- based ACT regimens recommended in the 2nd edition of the WHO malaria treatment guidelines; artemether+lumefantrine (AL), dihydroartemisinin+piperaquine (DHA+PPQ) and artesunate (AS) plus amodiaquine (AQ), mefloquine (MQ) or sulfadoxine-pyrimethamine (SP). Alternative age- thresholds were evaluated to further optimize the regimens. Results. Robust region specific weight-for-age references were created using >900.000 measurements from 167 data sources and 67 countries. The models accurately predicted observed regional weight-far-age distributions. Significant inter-regional variation existed in growth patterns (e.g. delayed growth spurt in Asia compared to Africa and Latin America) and attained growth. Dosing accuracies varied greatly by age and drug. ACT regimens with narrow therapeutic ranges (including MQ, AL, PPQ,) likely result in considerable dosing outside WHO recommended dose ranges. Suboptimal drug ratios in fixed-dose drug combinations contribute to low dose accuracies. Conclusions. Our reference and regimen modelling tools for the design of age-based dosing recommendations provide drug developers and policy makers with a powerful decision-support tool to optimize the safety and effectiveness of antimalarials dosed by age. The methods can further be extrapolated to other drugs from the WHO essential medicines list, and can be improved by incorporating pharmacokinetic data and safety data from post marketing surveillance when they become available. This work was supported by grants from the Liverpool School of Tropical Medicine, the British Medical Research Council, the European and Developing Countries Clinical Trials Partnership and the Drugs for Neglected Disease initiative.
APA, Harvard, Vancouver, ISO, and other styles
8

Molyneaux, Carrie-Anne. "Antimalarials based on the arylpiperazine privileged substructure." Master's thesis, University of Cape Town, 2005. http://hdl.handle.net/11427/6342.

Full text
Abstract:
Includes bibliographical references (leaves 118-124).
Based on a previous study, arylpiperazines (2-chlorophenylpiperazine, 2-ethoxyphenylpiperazine and phenylpiperazine) were found to be significantly more potent against the chloroquine-resistant (K1) strain than against the chloroquine-sensitive(DIO) strain. In other studies, 8-hydroxy-2-(di-n-propylamino)tetralin (8-0H-DPAT) has been identified as a potential antimalarial agent for the inhibition of the 5-hydroxytryptamine type 1A receptor in Plasmodium falciparum. A number of arylpiperazines are also known to target this receptor in other systems. Coupled with the potential role of arylpiperazines as replacements for the antimalarial 8-OH-OPA T, these results prompted a further investigation into the antiplasmodial properties of a broader range of simple un substituted and substituted arylpiperazines against a broader range of chloroquine-sensitive and chloroquine-resistant strains of PlasmodiumJalciparum.
APA, Harvard, Vancouver, ISO, and other styles
9

Tan, Bee San Fleckenstein Lawrence L. "Population pharmacokinetics of artesunate and its active metabolite dihydroartemisinin." [Iowa City, Iowa] : University of Iowa, 2009. http://ir.uiowa.edu/etd/442.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Duraisingh, Manoj Theodore. "Characterisation of resistance to artemisinin in Plasmodium falciparum." Thesis, London School of Hygiene and Tropical Medicine (University of London), 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.322662.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Antimalarials"

1

Ciach, Michelle. Novel antimalarials and sensitizing agents. Ottawa: National Library of Canada, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Silikas, Nikolaos. Rational drug design of protoberberine antimalarials. Manchester: University of Manchester, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Drugs for Neglected Diseases Initiative. The successful development of a fixed dose combination of artesunate plus amodiaquine antimalarial: Pioneering ways of working through innovative partnerships 2002-2015. [Geneva]: DNDi, 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Silvia, Blair, ed. Plantas antimaláricas: Una revisión bibliográfica. Medellín, Colombia: Editorial Universidad de Antioquia, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kiang, Tony K. L., Kyle John Wilby, and Mary H. H. Ensom. Clinical Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antimalarials. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-10527-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Depoortere, Evelyn. Compliance to the combination of sulfadozine-pyrimethamine, and artesunate: Maheba Refugee Settlement, Zambia : final report. Lusaka?]: Epicentre, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Jan, Bruce-Chwatt Leonard, ed. Chemotherapy of malaria. 2nd ed. Geneva: World Health Organization, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Vanuatu. Department of Health. Malaria Control Unit. Malaria handbooks for health workers in Vanuatu. Vanuatu: Malaria Control Unit Department of Health, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Li, Qigui. Antimalarial drugs: Age of the artemisinins. Hauppauge, N.Y: Nova Science, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

South Africa) TPS Drug Information Centre (Pretoria. Malaria prophylaxis: The South African viewpoint. Pretoria: Dept. of National Health and Population Development, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Antimalarials"

1

Tull, Thomas, and Mark Goodfield. "Antimalarials." In Handbook of Systemic Drug Treatment in Dermatology, 61–66. 3rd ed. London: CRC Press, 2022. http://dx.doi.org/10.1201/9781003016786-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Henry, David W. "Acridine Antimalarials." In Chemistry of Heterocyclic Compounds: A Series Of Monographs, 829–50. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2008. http://dx.doi.org/10.1002/9780470186596.ch19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kiang, Tony K. L., Kyle John Wilby, and Mary H. H. Ensom. "Effects of Antimalarials on the Pharmacokinetics of Co-Administered Antimalarials." In Clinical Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antimalarials, 87–117. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-10527-7_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bhattacharjee, Mrinal K. "Antifungals, Antimalarials, and Antivirals." In Chemistry of Antibiotics and Related Drugs, 175–95. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-40746-3_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bhattacharjee, Mrinal K. "Antifungals, Antimalarials, and Antivirals." In Chemistry of Antibiotics and Related Drugs, 203–26. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-07582-7_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kiang, Tony K. L., Kyle John Wilby, and Mary H. H. Ensom. "Pharmacokinetic Drug Interactions Affecting Antimalarials." In Clinical Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antimalarials, 27–55. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-10527-7_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kiang, Tony K. L., Kyle John Wilby, and Mary H. H. Ensom. "Drug Interaction Potential of Antimalarial Drugs Based on Known Metabolic Properties of Antimalarials." In Clinical Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antimalarials, 17–25. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-10527-7_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Keystone, J. S. "Advantages and Disadvantages of Antimalarials for Chemoprophylaxis." In Travel Medicine, 102–12. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-73772-5_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ecker, Andrea, Adele M. Lehane, and David A. Fidock. "Molecular Markers of Plasmodium Resistance to Antimalarials." In Treatment and Prevention of Malaria, 249–80. Basel: Springer Basel, 2011. http://dx.doi.org/10.1007/978-3-0346-0480-2_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Vaidya, Akhil B. "Naphthoquinones: Atovaquone, and Other Antimalarials Targeting Mitochondrial Functions." In Treatment and Prevention of Malaria, 127–39. Basel: Springer Basel, 2011. http://dx.doi.org/10.1007/978-3-0346-0480-2_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Antimalarials"

1

Dreve, Simina, Iren Kacso, Adriana Popa, Oana Raita, A. Bende, Gh Borodi, I. Bratu, and Mihaela D. Lazar. "Chitosan-based nanocarriers for antimalarials." In PROCESSES IN ISOTOPES AND MOLECULES (PIM 2011). AIP, 2012. http://dx.doi.org/10.1063/1.3681956.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Desai, Krisha, Majid Zeidi, Hee Joo Kim, and Victoria P. Werth. "II-09 Immunologic properties of cutaneous lupus erythematosus (CLE) patients refractory to antimalarials compared to patients that respond to antimalarials." In LUPUS 21ST CENTURY 2018 CONFERENCE, Abstracts of the Fourth Biannual Scientific Meeting of the North and South American and Caribbean Lupus Community, Armonk, New York, USA, September 13 – 15, 2018. Lupus Foundation of America, 2018. http://dx.doi.org/10.1136/lupus-2018-lsm.108.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Silva, Gabriela D. da, Piero Bagnaresi, and Rodrigo L. O. R. Cunha. "Organoselenium functionalized nitrogen heterocycles: a proposition for new antimalarials." In 15th Brazilian Meeting on Organic Synthesis. São Paulo: Editora Edgard Blücher, 2013. http://dx.doi.org/10.5151/chempro-15bmos-bmos2013_20131014142313.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wang, F., W. Zhang, X. Feng, and L. Sun. "FRI0320 Antimalarials protective effects in systemic lupus erythematosus in china." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.3073.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ma, Wenchuan, James Lutsko, Jeffrey Rimer, and Peter Vekilov. "Antagonistic Cooperativity between Antimalarials Controlling Hematin Crystallization by Attenuation of Step Pinning." In Goldschmidt2020. Geochemical Society, 2020. http://dx.doi.org/10.46427/gold2020.1689.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Asghari-Khiavi, Mehdi, Jitraporn Vongsvivut, Adam Mechler, Don McNaughton, Bayden R. Wood, D. Scott Bohle, P. M. Champion, and L. D. Ziegler. "Vibrational Spectroscopy Study of the Interaction of Quinoline Antimalarials with Ferriprotoporphyrin IX." In XXII INTERNATIONAL CONFERENCE ON RAMAN SPECTROSCOPY. AIP, 2010. http://dx.doi.org/10.1063/1.3482885.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Canhão, H., JE Fonseca, JC Teixeira Costa, JA Pereira Silva, and M. Viana Queiroz. "FRI0107 Toxicity of antimalarials in the treatment of portuguese patients with systemic lupus erythematosus." In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.142.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

DUBE, PRITAM, NITIN JAIN, and PRADEEP DESHMUKH. "Development of Triazine-4,6-diamines derivatives as potential Antimalarials: In-Silico Analysis." In The 21st International Electronic Conference on Synthetic Organic Chemistry. Basel, Switzerland: MDPI, 2017. http://dx.doi.org/10.3390/ecsoc-21-04805.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Pons-Estel, G., D. Wojdyla, M. Ugarte-Gil, F. Caeiro, E. Soriano, M. García, C. Drenkard, et al. "192 Protective effect of antimalarials on the risk of damage accrual in systemic lupus erythematosus." In LUPUS 2017 & ACA 2017, (12th International Congress on SLE &, 7th Asian Congress on Autoimmunity). Lupus Foundation of America, 2017. http://dx.doi.org/10.1136/lupus-2017-000215.192.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Jochims, I., L. M. H. Mota, L. Muniz, D. F. Vasconcelos, and L. L. Santos-Neto. "SAT0654 Association of prednisone and antimalarials and echocardiographic findings in asymptomatic cardiovascular patients with sle." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.6043.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Antimalarials"

1

Dhawan, B. N. Evaluation of New Antimalarials. Development of New Antimalarial Drugs. Fort Belvoir, VA: Defense Technical Information Center, September 1991. http://dx.doi.org/10.21236/ada242409.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rayhim, Rayhana, and Jeannie S. Strobl. Augmentation of the Differentiation Response to Antitumor Antimalarials. Fort Belvoir, VA: Defense Technical Information Center, July 2004. http://dx.doi.org/10.21236/ada432050.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Murphy, Kevin. Design and Synthesis of Novel Chloroquine-based Antimalarials. Portland State University Library, January 2000. http://dx.doi.org/10.15760/etd.2619.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Avery, Mitchell A. Directed Synthesis of New Antimalarials Using Computer Aided Drug Design. Fort Belvoir, VA: Defense Technical Information Center, October 1995. http://dx.doi.org/10.21236/ada303867.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Avery, Mitchell A. Directed Synthesis of New Antimalarials using Computer Aided Drug Design. Fort Belvoir, VA: Defense Technical Information Center, October 1995. http://dx.doi.org/10.21236/ada304919.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

San Pedro, Ekaterina Ellyce. A brief historical overview of the antimalarials chloroquine and artemisinin: An investigation into their mechanisms of action and discussion on the predicament of antimalarial drug resistance. Ames (Iowa): Iowa State University, January 2021. http://dx.doi.org/10.31274/cc-20240624-10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Basagoitia, Andrea. Do home- or community-based programmes for treating malaria improve health outcomes? SUPPORT, 2017. http://dx.doi.org/10.30846/170313.

Full text
Abstract:
Prompt access to diagnosis and treatment with effective antimalarial drugs is a central component of malaria control. Home- or community-based programmes for managing malaria are one strategy that has been proposed to overcome the geographical barrier to malaria treatment. In these programmes people living in rural settings, such as mothers, volunteers, or community health workers, are trained to recognise fever and provide antimalarial medicines at a low cost or for free.
APA, Harvard, Vancouver, ISO, and other styles
8

Ager, Arba L. Evaluation of Antimalarial Agents. Fort Belvoir, VA: Defense Technical Information Center, May 1998. http://dx.doi.org/10.21236/ada382495.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hoffman, Marshall M. Design, Synthesis and Testing of Novel Antimalarial. Fort Belvoir, VA: Defense Technical Information Center, May 2006. http://dx.doi.org/10.21236/ada452979.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kendrick, Kelsie. Mimicking Metabolism of a Reversed Chloroquine Antimalarial. Portland State University Library, January 2000. http://dx.doi.org/10.15760/etd.2083.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Antimalarials' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography